We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Nova Alternative RNA Splicing Targets Neuronal Proteins

By Biotechdaily staff writers
Posted on 26 Nov 2003
A new study describes a method to purify protein-RNA complexes from mouse brain that allows researchers to identify an array of RNA molecules regulated by Nova, an RNA-binding protein that regulates alternative RNA splicing.

Nova proteins are neuron-specific antigens targeted in paraneoplastic opsoclonus myoclonus ataxia (POMA), an autoimmune neurologic disease characterized by abnormal motor inhibition. More...
Nova proteins regulate neuronal pre-messenger RNA splicing by directly binding to RNA.

RNA splicing is an essential, precisely regulated post-transcriptional process that occurs prior to mRNA translation. A gene is first transcribed into a pre-messenger RNA (pre-mRNA), which is a copy of the genomic DNA containing intronic regions destined to be removed during pre-mRNA processing (RNA splicing), as well as exonic sequences that are retained within the mature mRNA. During RNA splicing, exons can either be retained in the mature message or targeted for removal in different combinations to create a diverse array of mRNAs from a single pre-mRNA, a process referred to as alternative RNA splicing.

Alternative splice events that affect the protein coding region of the mRNA will give rise to proteins that differ in their sequence and therefore in their activities. Alternative splicing within the noncoding regions of the RNA can result in changes in regulatory elements such as translation enhancers or RNA stability domains, which may have a dramatic effect on the level of protein expression.

Investigators at Rockefeller University (New York, NY, USA; www.rockefeller.edu) employed a technique called cross-linking and immunoprecipitation (CLIP) to chemically bond the NOVA protein to its RNA targets. In a novel adaptation of this method, they applied it to intact mouse brains in order to trap the protein-RNA complexes as they are in situ. In the November 14, 2003, issue of Science, they reported that 34 transcripts were identified multiple times by Nova CLIP. Three-quarters of these encoded proteins functioned at the neuronal synapse, and one-third were involved in neuronal inhibition.

"Looking at these targets as a group, they have a tremendous biological coherence to them,” observed senior author Dr. Robert B. Darnell, a Howard Hughes Medical Institute investigator at Rockefeller University. "Almost 70% of them are RNAs that have something to do with the neuronal synapse. One-third of the Nova synaptic RNA targets encode proteins involved in inhibiting neuronal function. Regulating neuronal inhibition plays a key role in the balance-controlling nervous system function normally as well as in neurological disorders such as epilepsy.”



Related Links:
Rockefeller University

Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
ESR Analyzer
miniiSED™
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.